Longeveron Inc. Common Stock (LGVN) Stock Price

LGVNStock

$0.68+4.75%52W

Market Cap$21.68M

P/E—

PEG Ratio—

Div yield—

Beta-0.26

LGVN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)37.93%

Price vs S&P 500 (4W)36.28%

VGM Score47.81

Book Value / Share (Quarterly)$0.52

P/TBV (Annual)3.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.63%

Cash Flow / Share (Quarterly)$-0.61

Price vs S&P 500 (YTD)53.61%

Gross Margin (TTM)65.13%

Net Profit Margin (TTM)-1844.49%

EPS (TTM)$-1.17

10-Day Avg Trading Volume0.78M

EPS Excl Extra (TTM)$-1.17

Revenue Growth (5Y)-26.60%

EPS (Annual)$-1.29

ROI (Annual)-400.07%

Gross Margin (Annual)66.97%

Net Profit Margin (5Y Avg)-1685.60%

Cash / Share (Quarterly)$0.51

Revenue Growth QoQ (YoY)4.46%

ROA (Last FY)-221.26%

Revenue Growth TTM (YoY)-45.35%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-185.61%

Operating Margin (TTM)-1881.66%

Cash Flow / Share (Annual)$-0.84

P/B Ratio1.38x

P/B Ratio (Quarterly)1.90x

Net Income / Employee (Annual)$-873,200

EV / Revenue (TTM)5.17x

Net Interest Coverage (TTM)-4260.25x

ROA (TTM)-140.67%

EPS Incl Extra (Annual)$-1.29

Current Ratio (Annual)1.33x

Quick Ratio (Quarterly)3.64x

3-Month Avg Trading Volume0.40M

52-Week Price Return4.75%

Revenue / Employee (TTM)$46,800

Tangible BV / Share (Quarterly)$0.45

P/S Ratio (Annual)18.38x

Asset Turnover (Annual)0.12x

52-Week High$1.23

Operating Margin (5Y Avg)-1686.28%

EPS Excl Extra (Annual)$-1.29

CapEx CAGR (5Y)17.87%

26-Week Price Return49.18%

Quick Ratio (Annual)1.17x

13-Week Price Return16.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.88x

Enterprise Value$6.28M

Revenue / Share Growth (5Y)-53.11%

Asset Turnover (TTM)0.08x

Revenue / Employee (Annual)$46,100

Pretax Margin (Annual)-1893.58%

Cash / Share (Annual)$0.20

3-Month Return Std Dev72.40%

Gross Margin (5Y Avg)52.55%

Net Income / Employee (TTM)$-862,700

ROE (Last FY)-400.07%

Net Interest Coverage (Annual)-73.31x

EPS Basic Excl Extra (Annual)$-1.29

Receivables Turnover (TTM)25.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.17

Receivables Turnover (Annual)12.76x

ROI (TTM)-202.41%

P/S Ratio (TTM)18.13x

Pretax Margin (5Y Avg)-1685.60%

Revenue / Share (Annual)$0.07

Tangible BV / Share (Annual)$0.15

Price vs S&P 500 (52W)-13.56%

Year-to-Date Return65.57%

5-Day Price Return6.43%

EPS Normalized (Annual)$-1.29

ROA (5Y Avg)-113.92%

Net Profit Margin (Annual)-1893.58%

Month-to-Date Return19.43%

Cash Flow / Share (TTM)$-0.89

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-1942.20%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-185.61%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.17

P/TBV (Quarterly)2.21x

P/B Ratio (Annual)1.90x

Pretax Margin (TTM)-1844.49%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)13.39%

Beta-0.26x

Revenue / Share (TTM)$0.05

ROE (TTM)-202.41%

52-Week Low$0.47

vGradeC

gGradeD

mGradeB

vgmGradeC

LGVN Earnings Surprise History

Q2 25-0.33est. -0.35

Q3 25-0.39est. -0.26

Q4 25-0.22est. -0.37

Q1 26-0.19est. -0.17

Q2 26-0.19est. -0.19

LGVN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LGVNLongeveron Inc. Common Stock	C	D	B	$0.68
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Longeveron Inc. Common Stock

Longeveron Inc is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic stem cell therapy designed to promote tissue repair and regeneration in aging-related and life-threatening diseases. The company is advancing three pipeline programs targeting Hypoplastic Left Heart Syndrome, Alzheimer's disease, and aging-related frailty.